The US has its first and only oral COVID-19 post-exposure prophylaxis (PEP) on its way, after a Phase III trial of the drug ensitrelvir met goals required for approval by the US Food and Drug Administration (FDA).
The war in Iran threatens to disrupt international travel to Asia, where the tourism industry has yet to fully recover from the the COVID19 pandemic ...